Published: March 4, 2024 at 2:20 a.m. ET
Written by Christian Moes Laursen
AstraZeneca announced that it has received two EU marketing authorizations from the European Medicines Agency for its anticancer drug Dato-DXd, which it co-developed with Japan's Daiichi Sankyo.
The pharmaceutical giant announced on Monday that the EMA has granted marketing authorization for Dato-DXd in the treatment of lung and breast cancer.
…
Written by Christian Moes Laursen
AstraZeneca announced that it has received two EU marketing authorizations from the European Medicines Agency for its anticancer drug Dato-DXd, which it co-developed with Japan's Daiichi Sankyo.
The pharmaceutical giant announced on Monday that the EMA has granted marketing authorization for Dato-DXd in the treatment of lung and breast cancer.
AstraZeneca said that after validation, a scientific review process by the EMA's Committee for Medicinal Products for Human Use will begin.
Susan Galbraith, executive vice president of oncology research and development, said: “Today's dual validation of our applications in lung cancer and breast cancer confirms that this potential medicine is a viable option for patients with two of the most common cancers in Europe. “This brings us a meaningful step closer to redefining treatment expectations.” .
Dato-DXd, or datopotamab deruxtecan, is a specially designed antibody-drug conjugate discovered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo.
Email Christian Moess Laursen at christian.moess@wsj.com.
